Available from: [3] Mehta A, Marso SP, Neeland IJ
Aleniglipron (Structure Therapeutics) -- Phase 2# Aleniglipron has produced the most competitive oral weight loss data to date: ACCESS: 11.3% placebo-adjusted weight loss at 36 weeks (120 mg) ACCESS II: 15.3% placebo-adjusted weight loss at 36 weeks (240 mg) Low-dose initiation (2.5 mg) significantly improved tolerability Phase 3 planned for mid-2026 At 36 weeks, aleniglipron's trajectory suggests it could approach injectable-level efficacy with longer treatment duration
Semaglutide sold as Wegovy is currently the most commonly prescribed GLP-1 medication for managing obesity
Gastroenterology 2017: Western dietary pattern increases, and prudent dietary pattern decreases, risk of incident diverticulitis in a prospective cohort study [prospective cohort study, weak evidence] American Journal of Gastroenterology 2017: Adherence to a Healthy Lifestyle is Associated With a Lower Risk of Diverticulitis among Men [observational study, weak evidence] Colorectal Disease 2017: An unrestricted diet for uncomplicated diverticulitis is safe: results of a prospective diverticulitis diet study [prospective cohort study, weak evidence] This is based on consistent clinical experience of practitioners who use low carb diets
Book Your Free Consultation Online Consultation Online!
The platforms AI doctor provides personalized, modern medical advice by synthesizing the latest peer-reviewed research